Stephen Saad's Aspen secures royalty-free rights to Merck's once-monthly HIV pill
Stephen Saad's Aspen Pharmacare is one of seven drugmakers licensed to make Merck's once-monthly HIV prevention pill in 129 countries.
Aspen Pharmacare
Aspen, controlled by tycoon Stephen Saad, wins Canadian approval for generic Ozempic
Stephen Saad's Aspen Pharmacare has won Canadian approval for a generic Ozempic, but an ingredient supply failure will keep it off shelves for months.
Aspen Pharmacare's $1.6 billion APAC sale adds $33 million to Stephen Saad's net worth
Aspen Pharmacare shares surged 7% after completing its R27bn APAC sale, adding approximately R550 million ($33.5 million) to Stephen Saad's fortune in a single trading session.
Africa CDC and Stephen Saad's Aspen strike talks on a plan to end Africa's vaccine import dependency
Africa CDC and Aspen Pharmacare announced advanced talks on a long-term vaccine supply framework on the sidelines of the Africa Forward Summit in Nairobi.
Stephen Saad's Aspen Pharmacare predicts double-digit growth despite tough first half
Aspen Pharmacare reported a steep drop in first-half earnings due to one-off restructuring costs but expects double-digit profit growth by year-end.
Stephen Saad's Aspen Pharmacare is racing to get Generic Ozempic approved in Canada by September
Africa's largest drugmaker is gunning for a Canadian green light on its generic version of Ozempic's key ingredient before summer ends.
Aspen Pharmacare founder Stephen Saad eyes Canada as first proving ground for generic Ozempic rivals
Aspen founder Stephen Saad wants Canada to be the proving ground for generic semaglutide, as competitors race regulators and supply constraints.
South African pharma tycoon Stephen Saad’s Aspen to sell Asia-Pacific assets for $1.59 billion
Stephen Saad’s Aspen will sell most Asia-Pacific operations for $1.59 billion as the drugmaker trims debt and reshapes its global footprint.
South African tycoon Stephen Saad loses $19 million from Aspen stake
Stephen Saad’s Aspen Pharmacare stake loses $19 million as shares fall, highlighting mounting pressure on Africa’s largest drugmaker.
Aspen Pharmacare investors eye CEO’s $1.2 million pay after weak results
Aspen investors head into December AGM after years of weak earnings and share losses, ready to question whether CEO pay still makes sense.
South African executive Gus Attridge loses $10 million as Aspen shares fall
South African pharma leader Gus Attridge sees a $10.7 million drop in his Aspen stake as the drugmaker’s shares slide and investor concerns deepen in 2025.
Aspen’s market slide wipes $20 million off Stephen Saad’s stake
Stephen Saad’s Aspen Pharmacare stake drops by $20 million as the company’s stock slips 6 percent on the Johannesburg Stock Exchange (JSE).
South African pharma tycoon Stephen Saad’s Aspen stake tops $340 million
Aspen Pharmacare shares edge higher, boosting CEO Stephen Saad’s holdings above $340 million despite the stock’s 37% year-to-date decline.
South Africa’s Stephen Saad expects $50 million sales from Aspen’s weight loss drug
South African pharma tycoon Stephen Saad says Aspen’s weight loss drug could reach $50 million in sales within two years.
South African pharma tycoon Gus Attridge loses $15.8 million on Aspen stake
Aspen co-founder Gus Attridge loses $15.8 million in three weeks as drug stocks fall, cutting Aspen’s value below $2.6 billion.
South African pharma tycoon Stephen Saad loses $44 million from Aspen stake
Aspen Pharmacare shares slide 33 percent, cutting Stephen Saad’s stake by $44 million amid global pharma pressures.